Cargando…

Pharmacist-led olaparib follow-up service for ambulatory ovarian cancer patients: A prospective study in a tertiary specialized cancer hospital in China

Purpose: To establish a pharmacist-led olaparib follow-up program for ovarian cancer patients, provide patient education, get information on adverse drug reactions (ADRs), and identify and manage drug-related problems. Methods: Ambulatory adult patients with ovarian cancer receiving olaparib were en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yanting, Du, Di, Yang, Jun, Lau, Alan H., Dai, Yuanyuan, Qin, Wangjun, Li, Ning, Li, Guohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795018/ https://www.ncbi.nlm.nih.gov/pubmed/36588742 http://dx.doi.org/10.3389/fphar.2022.1037726

Ejemplares similares

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Effects of Pharmacist-Led Clinical Pathway/Order Sets on Cancer Patients: A Systematic Review
por: Tan, Zhiyuan, et al.
Publicado: (2021)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Pharmacist-led iodinated contrast media infusion risk assessment service
por: Jiang, Huiyan, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
por: Li, Na, et al.
Publicado: (2021)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
por: Shu, Yamin, et al.
Publicado: (2022)

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
por: Su, Dan, et al.
Publicado: (2021)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

Utilizing Pharmacist-Led Telehealth Services in Ambulatory Patients with Heart Failure
por: Lugo Zamora, Ivanna L., et al.
Publicado: (2023)

The Effectiveness of Clinical Pharmacist-Led Consultation in the Treatment of Infectious Diseases: A Prospective, Multicenter, Cohort Study
por: Zhang, Jiaxing, et al.
Publicado: (2020)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Comparison of Adverse Reactions Caused by Olaparib for Different Indications
por: Zhou, Yujing, et al.
Publicado: (2022)

A pharmacist-led medication review service with a deprescribing focus guided by implementation science
por: Alaa Eddine, Nada, et al.
Publicado: (2023)

The Impact of a Multifaceted Pharmacist-Led Antimicrobial Stewardship Program on Antibiotic Use: Evidence From a Quasi-Experimental Study in the Department of Vascular and Interventional Radiology in a Chinese Tertiary Hospital
por: Xu, Jinhui, et al.
Publicado: (2022)

Impact of a Multifaceted Pharmacist-Led Intervention on Antimicrobial Stewardship in a Gastroenterology Ward: A Segmented Regression Analysis
por: Du, Yaling, et al.
Publicado: (2020)

Evaluation of a clinical pharmacist-led antimicrobial stewardship program in a neurosurgical intensive care unit: a pre-and post-intervention cohort study
por: Yu, Jing, et al.
Publicado: (2023)

Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic
por: Li, Xiaoye, et al.
Publicado: (2020)

Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre
por: Pelletier, Ryan
Publicado: (2021)

Olaparib-induced pseudoporphyria in a patient with ovarian cancer
por: Clark, Abigale, et al.
Publicado: (2023)

Pharmacist-Led Self-management Interventions to Improve Diabetes Outcomes. A Systematic Literature Review and Meta-Analysis
por: van Eikenhorst, Linda, et al.
Publicado: (2017)

Effectiveness of a Patient-Tailored, Pharmacist-Led Intervention Program to Enhance Adherence to Antihypertensive Medication: The CATI Study
por: van der Laan, Danielle M., et al.
Publicado: (2018)

The Clinical Pharmacist-Led Consultation for Infectious Diseases in Guizhou Province, China: A Survey Among Hospital Pharmacies
por: Zhang, Jiaxing, et al.
Publicado: (2020)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Pharmacist-Led Intervention to Enhance Medication Adherence in Patients With Acute Coronary Syndrome in Vietnam: A Randomized Controlled Trial
por: Nguyen, Thang, et al.
Publicado: (2018)

Pharmacist‐Led Intervention on the Inappropriate Use of Stress Ulcer Prophylaxis Pharmacotherapy in Intensive Care Units: A Systematic review
por: Xu, Peipei, et al.
Publicado: (2021)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
por: Montemorano, Lauren, et al.
Publicado: (2019)

Impact of Pharmacist-Led Diabetes Self-Care Education on Patients With Type 2 Diabetes in Pakistan: A Randomized Controlled Trial
por: Bukhsh, Allah, et al.
Publicado: (2022)

Impact of clinical pharmacist-led intervention for drug-related problems in neonatal intensive care unit a randomized controlled trial
por: Yalçın, Nadir, et al.
Publicado: (2023)

A randomized controlled trial to evaluate the impact of pharmacist-led clinical interventions on the health-related quality of life among TB patients
por: Khan, Farman Ullah, et al.
Publicado: (2023)

Anti-Cholinergic Drug Burden Among Ambulatory Elderly Patients in a Nigerian Tertiary Healthcare Facility
por: Fadare, Joseph O., et al.
Publicado: (2021)

Noncoding RNAs in the Glycolysis of Ovarian Cancer
por: Zhang, Chunmei, et al.
Publicado: (2022)

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
por: Nie, Jing, et al.
Publicado: (2023)

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
por: Shaw, Heather M, et al.
Publicado: (2013)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy
por: Himeji, Daisuke, et al.
Publicado: (2021)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

Evaluation of a Pharmacist-Led Remote Warfarin Management Model Using a Smartphone Application (Yixing) in Improving Patients’ Knowledge and Outcomes of Anticoagulation Therapy
por: Jiang, Shudan, et al.
Publicado: (2021)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_emmio4bgps68n56so9jatmfg23